Is Biofil Chemicals and Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Biofil Chemicals and Pharmaceuticals CMP Rs 32 (24 Sep 2026). Market cap Rs 52 Cr. ROE 12.92%. P/E 107.53x versus Industry P/E 51.57x.

Updated: 24 Sept 2026 • 11:33 am

Posted by:

Is Biofil Chemicals and Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Biofil Chemicals and Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 12.92% return on equity and a P/E of 107.53x against an Industry P/E of 51.57x. Whether Biofil Chemicals and Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Biofil Chemicals and Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 32 as of 24 September 2026, within its 52-week range of Rs 25.60 to Rs 46.34. Biofil Chemicals & Pharmaceuticals Ltd manufactures pharmaceutical formulations.

Biofil Chemicals and Pharmaceuticals sits in the Healthcare sector, and its 12.92% ROE and 107.53x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Biofil Chemicals and Pharmaceuticals

Biofil Chemicals & Pharmaceuticals Ltd manufactures pharmaceutical formulations. It manufactures pharmaceutical formulations at a micro-cap scale, with a very small per-share earnings base that amplifies its reported P/E multiple. At a market capitalisation of Rs 52 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Biofil Chemicals and Pharmaceuticals the Best Stock in Its Sector?

Biofil Chemicals and Pharmaceuticals makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 12.92% ROE with a 107.53x P/E against the sector's 51.57x Industry P/E. Biofil Chemicals and Pharmaceuticals' 107.53x P/E is well above the 51.57x Industry P/E; its 12.92% ROE is reasonable, but the extremely small per-share earnings base means the headline multiple should be read with the company's micro-cap scale in mind.

Metric	Biofil Chemicals and Pharmaceuticals
CMP (NSE)	Rs 32.10
52-Week High / Low	Rs 46.34 / Rs 25.60
Market Cap	Rs 52 Cr
P/E (TTM) vs Industry P/E	107.53x vs 51.57x
P/B	2.43
ROE	12.92%
EPS (TTM)	Rs 0.30
Dividend Yield	0.00%
Debt to Equity	0.14

Compare Biofil Chemicals and Pharmaceuticals Against Other Healthcare Sector Stocks

How Biofil Chemicals and Pharmaceuticals Compares Against Its Healthcare Sector Peers

The table below sets Biofil Chemicals and Pharmaceuticals against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Biofil Chemicals and Pharmaceuticals	52	107.53	12.92%	0.14
Bal Pharma	172	23.72	7.64%	1.94
Beta Drugs	2,425	52.41	16.95%	0.60
Peer average (2 companies)	-	38.06	12.29%	1.27

Against this peer set, Biofil Chemicals and Pharmaceuticals's 12.92% ROE is above the 12.29% peer average, and its P/E of 107.53x runs above the peer average of 38.06x. Biofil Chemicals and Pharmaceuticals' 107.53x P/E is well above the 51.57x Industry P/E; its 12.92% ROE is reasonable, but the extremely small per-share earnings base means the headline multiple should be read with the company's micro-cap scale in mind.

What Makes Biofil Chemicals and Pharmaceuticals Worth Watching in Healthcare

Solid ROE: A 12.92% ROE is a reasonable figure for a small pharmaceutical formulations manufacturer.
Low leverage: A debt to equity ratio of 0.14 is manageable for a smaller-scale pharma manufacturer.
Very small, thinly traded scale: At a market capitalisation of Rs 52 Cr, Biofil Chemicals and Pharmaceuticals trades at a fraction of the scale of the larger Healthcare names used for comparison.

Biofil Chemicals and Pharmaceuticals Valuation: Is It Justified?

Biofil Chemicals and Pharmaceuticals' 107.53x P/E is well above the 51.57x Industry P/E; its 12.92% ROE is reasonable, but the extremely small per-share earnings base means the headline multiple should be read with the company's micro-cap scale in mind. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Bharat Bijlee the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Biofil Chemicals and Pharmaceuticals and other Healthcare sector stocks.

How to Track Biofil Chemicals and Pharmaceuticals Before You Invest

Before deciding whether Biofil Chemicals and Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Biofil Chemicals and Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Biofil Chemicals and Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 12.92% ROE and a P/E of 107.53x against a 51.57x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Biofil Chemicals and Pharmaceuticals the best stock in its sector?

Ans. Biofil Chemicals and Pharmaceuticals has a 12.92% ROE and trades at 107.53x P/E against a 51.57x Industry P/E, and compares above the peer average ROE of 12.29% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Biofil Chemicals and Pharmaceuticals?

Ans. Biofil Chemicals and Pharmaceuticals was trading at Rs 32.10 on the NSE as of 24 September 2026, within its 52-week range of Rs 25.60 to Rs 46.34.

What sector does Biofil Chemicals and Pharmaceuticals belong to?

Ans. Biofil Chemicals and Pharmaceuticals is classified under the Healthcare sector on Univest.

How does Biofil Chemicals and Pharmaceuticals compare to its sector peers on P/E?

Ans. Biofil Chemicals and Pharmaceuticals's P/E of 107.53x is above the 38.06x average of the 2 named peers compared in this article.

What is Biofil Chemicals and Pharmaceuticals's return on equity?

Ans. Biofil Chemicals and Pharmaceuticals reported a return on equity of 12.92%, which is above the 12.29% average of its named peers in this comparison.

Should I invest in Biofil Chemicals and Pharmaceuticals based on its sector position?

Ans. Biofil Chemicals and Pharmaceuticals's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.